TxCell SA said it raised $16 million in a third round of financing supported by the InnoBio fund, managed by CDC Entreprises, and existing shareholders Auriga Partners and Seventure Partners. InnoBio contributed about $7.8 million to the round.
You are browsing the archive for Seventure Partners - peHUB.
arGEN-X BV has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. arGEN-X is backed by OrbiMed Advisors, Seventure Partners, Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB.
Biophytis said it raised $2.6 million in a B round. Metabrain Research, a spinoff of Merck Serono, joined existing investors Seventure partners and CM-CIC Capital Prive in the financing.
Domain Therapeutics has completed a 2 million euro ($2.5 million) financing round. The biopharmaceutical company is based in Strasbourg, France. Half of the funds have been provided by a new investor, Seventure Partners and the other half has been committed by another new investor, SODIV and Domain’s existing shareholders – AIRFI, IP Growth, Auriga and [...]
arGEN-X, a biopharmaceutical company developing human monoclonal antibodies, has raised 27.5 million euro ($37 million) in Series B financing. OrbiMed Advisors and Seventure Partners co-led the round, which included participation from existing shareholders Forbion Capital Partners, Credit Agricole Private Equity, LSP, BioGeneration Ventures, the Erasmus Biomedical Fund, Thuja Capital and VIB. Mike Sheffery of OrbiMed will join the company’s board.
PhosphonicS, a UK-based developer of precious metal scavenger products, has raised £3.5 million in second-round funding. Seventure Partners led the round, and was joined by return backers like Regents Park Partners. PhosphonicS is a spinout from Queen Mary University of London.
BiancaMed, a Dublin, Ireland-based developer of sleep monitoring technology for conditions like sleep apnea, has raised €6 million in second-round funding. Seventure Partners led the round, and was joined by return backers ePlanet, Enterprise Ireland and ResMed. Go4Ventures served as placement agent.